Glenmark Pharmaceuticals USA launches authorized generic of Savella tablets
Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg
Glenmark's Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg is the authorized generic to Savella Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg
The initial consideration for the transaction is US$ 12 million
The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Stalevo Tablets
Company to launch product after the expiry of semaglutide patent in India
Developed using STEERLife’s proprietary FragMelt continuous processing platform, the approval marks a major breakthrough in pharmaceutical manufacturing
Subscribe To Our Newsletter & Stay Updated